SUN Farmacutica DO Brasil Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: SUN Farmacutica DO Brasil Ltda Pharmaceutical Import Records from India — 2 Products, $300.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Farmacutica DO Brasil Ltda — Pharmaceutical Importer Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

SUN Farmacutica DO Brasil Ltda

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $300.0K Total Trade · DGFT Verified

SUN Farmacutica DO Brasil Ltda is a pharmaceutical importer based in Brazil with a total trade value of $300.0K across 2 products in 1 therapeutic categories. Based on 6 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SUN Farmacutica DO Brasil Ltda sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

SUN Farmacutica DO Brasil Ltda — Import Portfolio & Supplier Network

SUN Farmacutica DO Brasil Ltda import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Farmacutica DO Brasil Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$904.5K	19	100.0%

SUN Farmacutica DO Brasil Ltda sources from 1 verified Indian supplier across 18 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Bortezomib for injection 3.5 MG/vial.	$100.0K	2
Capecitabina 500MG tablets Each	$50.0K	1
Sukhi injection 500MG b/no:had1994a	$50.0K	1
Zomi Each contains bortezomib Pack	$50.0K	1
Zomi Each contains bortezomib Pack	$50.0K	1
Exemestane tablets 25MG (exemestane)	$50.0K	1
Zomi Each contains bortezomib	$50.0K	1
Exemestane tablets 25MG (exemestane)	$50.0K	1
Mesila de imati(sun)TAB 100MG,pte0305b	$50.0K	1
Mesila de imati(sun)TAB 400mg3x10b	$50.0K	1
Nidhi cap 150MG Each capsule contains nintedanib equivalent to 150MG sap code :1158761 bno : haf1259a md.06/24	$50.0K	1
Abiraterone tablets USP 250MG Each tablet contains abiraterone acetate (we intend to claim under rodtep benefit scheme)	$50.0K	1
Pluto TAB 400MG 3x10b braz Each TAB	$48.2K	1
Pluto TAB 100MG 6x10b braz Each TAB	$46.6K	1
Anya tablets USP 1 MG (anastrozole)	$45.6K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bortezomib	Advanced Oncology	$200.0K	4	0.9%	2
2	Exemestane	Advanced Oncology	$100.0K	2	0.7%	14

SUN Farmacutica DO Brasil Ltda imports 2 pharmaceutical products across 1 categories into Brazil totaling $300.0K.

SUN Farmacutica DO Brasil Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SUN Farmacêutica do Brasil Ltda, established on April 25, 2002, is a Brazilian pharmaceutical importer and distributor specializing in the wholesale trade of human-use medications. The company's headquarters are located in Goiânia, Goiás, with an administrative office in Barueri, São Paulo. As a subsidiary of Sun Pharmaceutical Industries Limited, an Indian multinational pharmaceutical company, SUN Farmacêutica operates under the brand name "Sun Pharma." The company plays a significant role in Brazil's pharmaceutical distribution network, supplying a diverse range of pharmaceutical products to meet the country's healthcare needs.

2Distribution Network

SUN Farmacêutica do Brasil Ltda maintains a robust distribution network across Brazil, with its primary warehouse situated in Goiânia, Goiás. This central location facilitates efficient logistics and timely delivery of pharmaceutical products nationwide. The administrative office in Barueri, São Paulo, coordinates marketing and customer service operations, ensuring comprehensive coverage of the Brazilian market. While the company's distribution network is primarily focused within Brazil, its affiliation with Sun Pharmaceutical Industries Limited suggests potential access to international markets, enhancing its global reach.

3Industry Role

In Brazil's pharmaceutical supply chain, SUN Farmacêutica do Brasil Ltda functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from India, including tablets, capsules, syrups, and injections, and supplies these products to various healthcare providers, including hospitals, clinics, and pharmacies. This role is crucial in ensuring the availability of essential medications across the country, contributing to the overall efficiency and effectiveness of Brazil's healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Farmacutica DO Brasil Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SUN Farmacêutica do Brasil Ltda exhibits a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier, Sun Pharmaceutical Industries Limited. This exclusive sourcing strategy indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this dependency also poses risks; any disruptions in Sun Pharmaceutical Industries Limited's operations could directly impact SUN Farmacêutica's ability to meet market demand. The company's shipment data, comprising 19 shipments valued at $905,000, reflects a stable and ongoing relationship with its sole supplier, suggesting effective collaboration and mutual trust.

2Supply Chain Resilience

The resilience of SUN Farmacêutica do Brasil Ltda's supply chain is closely tied to its exclusive relationship with Sun Pharmaceutical Industries Limited. While this partnership ensures product consistency and quality, it also means that the company lacks alternative suppliers to mitigate potential disruptions. The diversity of formulations imported, with 18 unique products, indicates a broad product portfolio, which can help buffer against market fluctuations. However, the company's reliance on a single supplier for all imports suggests a need for strategic planning to enhance supply chain resilience, such as developing contingency plans and exploring additional supplier relationships.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the National Health Surveillance Agency (ANVISA) is the primary regulatory body overseeing the pharmaceutical sector. ANVISA is responsible for the registration, inspection, and monitoring of pharmaceutical products to ensure public health safety. Key legislation governing pharmaceutical imports includes the Health Surveillance Law (Law No. 9,782/1999) and the Regulatory Framework for Health Products (RDC No. 81/2008), which outline the procedures for importing and distributing pharmaceutical products in Brazil. For Indian generics to enter the Brazilian market, they must undergo ANVISA's registration process, demonstrating compliance with Brazilian standards and regulations.

2Import Licensing & GMP

Import licensing in Brazil requires pharmaceutical companies to obtain authorization from ANVISA, ensuring that imported products meet the country's health and safety standards. Good Manufacturing Practice (GMP) certification is mandatory for all pharmaceutical products entering Brazil. ANVISA recognizes GMP certifications from reputable international bodies, including the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply SUN Farmacêutica do Brasil Ltda must ensure that their manufacturing facilities hold valid GMP certifications from these recognized organizations to comply with Brazilian import regulations.

SUN Farmacutica DO Brasil Ltda — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SUN Farmacêutica do Brasil Ltda's focus on importing advanced oncology medications, specifically Bortezomib and Exemestane, aligns with the growing demand for cancer treatments in Brazil. The Brazilian Ministry of Health has prioritized oncology care, leading to increased investments in cancer treatment infrastructure and a rising patient population seeking advanced therapies. By concentrating on these therapeutic areas, SUN Farmacêutica addresses a critical healthcare need, positioning itself as a key supplier of essential oncology medications in the Brazilian market.

2Sourcing Profile

SUN Farmacêutica do Brasil Ltda's sourcing strategy is centered on importing generic drugs from India, leveraging the country's established pharmaceutical manufacturing capabilities and cost advantages. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a focus on ready-to-market products that meet Brazilian regulatory standards. India's compliance with international GMP certifications and its competitive pricing make it an attractive sourcing destination for SUN Farmacêutica, facilitating the efficient supply of quality medications to the Brazilian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to SUN Farmacutica DO Brasil Ltda

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Brazilian market by partnering with SUN Farmacêutica do Brasil Ltda. The company's exclusive sourcing from Sun Pharmaceutical Industries Limited indicates a potential openness to diversifying its supplier base. Indian exporters can explore this opportunity by ensuring compliance with Brazilian regulatory requirements, obtaining necessary certifications, and demonstrating the quality and efficacy of their products. Establishing a partnership with SUN Farmacêutica could facilitate access to the Brazilian market, leveraging the company's established distribution network and market knowledge.

2Requirements & Qualifications

Indian exporters aiming to supply SUN Farmacêutica do Brasil Ltda must ensure that their manufacturing facilities hold valid GMP certifications recognized by ANVISA, such as those from the EMA, WHO, or PIC/S. Additionally, products must comply with Brazilian labeling requirements, including Portuguese language labeling and serialization mandates. Exporters should also be prepared to navigate ANVISA's registration process, providing comprehensive documentation to demonstrate product quality, safety, and efficacy.

How to Approach

Frequently Asked Questions — SUN Farmacutica DO Brasil Ltda

What products does SUN Farmacutica DO Brasil Ltda import from India?

SUN Farmacutica DO Brasil Ltda imports 2 pharmaceutical products across 1 categories. Top imports: Bortezomib ($200.0K), Exemestane ($100.0K).

Who supplies pharmaceuticals to SUN Farmacutica DO Brasil Ltda from India?

SUN Farmacutica DO Brasil Ltda sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $904.5K).

What is SUN Farmacutica DO Brasil Ltda's total pharmaceutical import value?

SUN Farmacutica DO Brasil Ltda's total pharmaceutical import value from India is $300.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Farmacutica DO Brasil Ltda focus on?

SUN Farmacutica DO Brasil Ltda imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full SUN Farmacutica DO Brasil Ltda Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.